SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
April 25, 2023
 · 
13 min read
Pharm Country
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
March 31, 2023
 · 
14 min read
Pharm Country
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
March 3, 2023
 · 
13 min read
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
February 28, 2023
 · 
17 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business UpdateConference call to be held Tuesday, February 28, 2023 at 8:30 AM ET
February 24, 2023
 · 
1 min read
Drug Development
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 24, 2023
 · 
13 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 14, 2023
 · 
12 min read
Pharm Country
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
January 26, 2023
 · 
14 min read
Pharm Country
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Monday, January 9, 2023 at 9:45 AM PT
January 6, 2023
 · 
1 min read
FDA
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
December 28, 2022
 · 
19 min read
Business
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 10, 2022
 · 
9 min read
Pharm Country
TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business UpdateConference call to be held Thursday, November 10, 2022 at 8:30 AM ET
November 8, 2022
 · 
1 min read
Drug Development
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 26, 2022
 · 
7 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 13, 2022
 · 
8 min read
Pharm Country
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 9, 2022
 · 
1 min read
Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.
Drug Development
Clinical Catch-Up: 89bio, Tonix, Arcutis and More
August 28, 2022
 · 
4 min read
 · 
Mark Terry
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS